Skip to main content
  • More from ADA
    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes Care

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • Special Article Collections
    • ADA Standards of Medical Care
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • Special Article Collections
    • ADA Standards of Medical Care
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
    • ADA Peer Review
  • More from ADA
    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • My Cart

Search

  • Advanced search
Diabetes Care
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • Special Article Collections
    • ADA Standards of Medical Care
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • Special Article Collections
    • ADA Standards of Medical Care
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
    • ADA Peer Review
Online Letters: Observations

FGF23 in Type 2 Diabetic Patients: Relationship With Bone Metabolism and Vascular Disease

  1. Rebeca Reyes-Garcia1,2,
  2. Antonia Garcia-Martín1,3,
  3. Beatriz García-Fontana1,
  4. Sonia Morales-Santana1,4,
  5. Pedro Rozas-Moreno1,5 and
  6. Manuel Muñoz-Torres1
  1. 1Bone Metabolic Unit, Endocrinology Division, Hospital Universitario San Cecilio, Instituto de Investigación Biosanitaria de Granada, Granada, Spain
  2. 2Endocrinology Unit, Hospital General Universitario Rafael Mendez, Lorca, Murcia, Spain
  3. 3Endocrinology Unit, Hospital Comarcal del Noroeste, Caravaca de la Cruz, Murcia, Spain
  4. 4Proteomic Research Service, Fundación para la Investigación Biosanitaria de Andalucía Oriental—Alejandro Otero, Granada, Spain
  5. 5Endocrinology Division, Hospital General de Ciudad Real, Ciudad Real, Spain
  1. Corresponding author: Manuel Muñoz-Torres, mmt{at}mamuto.es.
Diabetes Care 2014 May; 37(5): e89-e90. https://doi.org/10.2337/dc13-2235
PreviousNext
  • Article
  • Figures & Tables
  • Info & Metrics
  • PDF
Loading

The relationship between fibroblast growth factor (FGF) 23 and vascular disease is well established in chronic kidney disease (CKD). Regarding serum FGF23 and bone fragility, there is contradictory data. Type 2 diabetes (T2D) is associated with higher rates of cardiovascular disease and fractures despite high bone mineral density (BMD), so the evaluation of FGF23 and its relationship with bone and cardiovascular disease in T2D is of interest. Our hypothesis was that serum FGF23 may be related to cardiovascular disease and bone metabolism (BMD, osteoporosis, and fractures) in T2D.

We performed a cross-sectional study including 68 T2D subjects and 45 subjects without diabetes. We analyzed the relationship between circulating FGF23, bone metabolism, cardiovascular events, and intima-media thickness (IMT).

There were no differences in FGF23 according to group. In the entire cohort, subjects with prevalent fracture and osteoporosis had lower FGF23 (20.9 ± 8.3 vs. 51.4 ± 38.9 pg/mL and 29.5 ± 15.6 vs. 52.4 ± 40.6 pg/mL, P < 0.05). In T2D, serum FGF23 was related to serum phosphorus (r = 0.484), lumbar spine T-score (r = 0.300), and femoral neck T-score (r = 0.252) and was inversely related to age (r = −0.496) (P < 0.05 for all). Differences according to osteoporosis, abnormal IMT, and diabetic nephropathy are shown in Fig. 1. In T2D, after linear regression analysis the main determinants of serum FGF23 were age (β = −0.406), glomerular filtration rate (β = −0.206), serum phosphorus (β = 0.299), osteoporosis (β = −0.235), and abnormal IMT (β = −0.253) (P < 0.05 for all).

Figure 1
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1

Serum FGF23 in T2D group (n = 68) by osteoporosis diagnosis, abnormal IMT, and diabetic nephropathy.

Our results showed a stronger correlation between FGF23 and BMD than previously found in elderly nondiabetic males (1,2). Serum FGF23 may reflect the osteocyte number, and T2D subjects have higher BMD. On the other hand, a different relationship between FGF23 and parathyroid hormone in diabetes has been reported apart from the presence of CKD (3), which may indicate a differentiated regulation and possibly different effects of FGF23 on bone metabolism in T2D compared with nondiabetic populations.

In our study, subjects with previous fractures have lower FGF23 concentrations, but no differences in T2D were found. Circulating FGF23 has been linked to fracture risk (4), although in another study FGF23 and hip fracture risk was not related (2). We consider that the relationship between FGF23 and fracture risk is not established.

T2D patients with abnormal IMT had lower FGF23, and abnormal IMT remained associated with FGF23 after linear regression analysis. However, FGF23 and established cardiovascular disease or aortic calcification was not related. Our findings may indicate a role in the development of atherosclerosis in T2D. Supporting the association between FGF23 and preclinical vascular disease, higher FGF23, even within the normal range, is independently associated with impaired vasoreactivity and increased arterial stiffness in the general population (5).

In summary, serum FGF23 is related to BMD and preclinical vascular disease in T2D patients. Our study suggests that effects of FGF23 in T2D may differ from other populations, although it must be confirmed in larger studies.

Article Information

Funding. This work was supported in part by Consejería de Salud y Bienestar Social Junta de Andalucia (PI-0514-2012) and RETICEF (RD06/0013/1014-RD12/0043/0014).

Duality of Interest. No potential conflicts of interest relevant to this article were reported.

Author Contributions. R.R.-G., A.G.-M., and M.M.-T. wrote the manuscript, contributed to discussion, and reviewed and edited the manuscript. B.G.-F., S.M.-S., and P.R.-M. researched data. R.R.-G. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

  • © 2014 by the American Diabetes Association.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.

References

  1. ↵
    1. Marsell R,
    2. Mirza MA,
    3. Mallmin H,
    4. et al
    . Relation between fibroblast growth factor-23, body weight and bone mineral density in elderly men. Osteoporos Int 2009;20:1167–1173
    OpenUrlCrossRefPubMed
  2. ↵
    1. Jovanovich A,
    2. Bùzková P,
    3. Chonchol M,
    4. et al
    . Fibroblast growth factor 23, bone mineral density, and risk of hip fracture among older adults: the cardiovascular health study. J Clin Endocrinol Metab 2013;98:3323–3331
    OpenUrlCrossRefPubMed
  3. ↵
    1. Muras K,
    2. Masajtis-Zagajewska A,
    3. Nowicki M
    . Diabetes modifies effect of high-phosphate diet on fibroblast growth factor-23 in chronic kidney disease. J Clin Endocrinol Metab 2013;98:E1901–E1908
    OpenUrlCrossRefPubMed
  4. ↵
    1. Mirza MA,
    2. Karlsson MK,
    3. Mellström D,
    4. et al
    . Serum fibroblast growth factor-23 (FGF-23) and fracture risk in elderly men. J Bone Miner Res 2011;26:857–864
    OpenUrlCrossRefPubMed
  5. ↵
    1. Mirza MA,
    2. Larsson A,
    3. Lind L,
    4. Larsson TE
    . Circulating fibroblast growth factor-23 is associated with vascular dysfunction in the community. Atherosclerosis 2009;205:385–390
    OpenUrlCrossRefPubMedWeb of Science
View Abstract
PreviousNext
Back to top
Diabetes Care: 37 (5)

In this Issue

May 2014, 37(5)
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by Author
  • Masthead (PDF)
Sign up to receive current issue alerts
View Selected Citations (0)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about Diabetes Care.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
FGF23 in Type 2 Diabetic Patients: Relationship With Bone Metabolism and Vascular Disease
(Your Name) has forwarded a page to you from Diabetes Care
(Your Name) thought you would like to see this page from the Diabetes Care web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
FGF23 in Type 2 Diabetic Patients: Relationship With Bone Metabolism and Vascular Disease
Rebeca Reyes-Garcia, Antonia Garcia-Martín, Beatriz García-Fontana, Sonia Morales-Santana, Pedro Rozas-Moreno, Manuel Muñoz-Torres
Diabetes Care May 2014, 37 (5) e89-e90; DOI: 10.2337/dc13-2235

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Add to Selected Citations
Share

FGF23 in Type 2 Diabetic Patients: Relationship With Bone Metabolism and Vascular Disease
Rebeca Reyes-Garcia, Antonia Garcia-Martín, Beatriz García-Fontana, Sonia Morales-Santana, Pedro Rozas-Moreno, Manuel Muñoz-Torres
Diabetes Care May 2014, 37 (5) e89-e90; DOI: 10.2337/dc13-2235
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Article Information
    • References
  • Figures & Tables
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Artifactual Hypoglycemia: An Old Term for a New Classification
  • Tyrosine Kinase Inhibitor Sunitinib Allows Insulin Independence in Long-standing Type 1 Diabetes
Show more Online Letters: Observations

Similar Articles

Navigate

  • Current Issue
  • Standards of Care Guidelines
  • Online Ahead of Print
  • Archives
  • Submit
  • Subscribe
  • Email Alerts
  • RSS Feeds

More Information

  • About the Journal
  • Instructions for Authors
  • Journal Policies
  • Reprints and Permissions
  • Advertising
  • Privacy Policy: ADA Journals
  • Copyright Notice/Public Access Policy
  • Contact Us

Other ADA Resources

  • Diabetes
  • Clinical Diabetes
  • Diabetes Spectrum
  • Scientific Sessions Abstracts
  • Standards of Medical Care in Diabetes
  • BMJ Open - Diabetes Research & Care
  • Professional Books
  • Diabetes Forecast

 

  • DiabetesJournals.org
  • Diabetes Core Update
  • ADA's DiabetesPro
  • ADA Member Directory
  • Diabetes.org

© 2021 by the American Diabetes Association. Diabetes Care Print ISSN: 0149-5992, Online ISSN: 1935-5548.